TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22546741
Drug: Patient-related attributes,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-related attributes, drug regimen characteristics, health status, patient-provider interaction
Study: 11274903
Drug: Trandolapril, 2
Normalized name: Trandolapril, 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril, 2 mg once daily in the morning
Study: 9588097
Drug: Tensitone (7.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tensitone (7.5% NaCl in 6% dextran 70, Infusia a.s., CR), administered at a dosage of 4 ml/kg
Study: 2712981
Drug: Immediate cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate cold therapy
Study: 2712981
Drug: Simulated therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated therapy (Control)
Study: 31274603
Drug: Caffeinated energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated energy drink (160 mg of caffeine)
Study: 30917863
Drug: Diabetes medication
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes medication adherence assessment using the Morisky Medication Adherence Scale (MMAS-8)
Study: 31912462
Drug: Filgotinib 100
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Filgotinib 100 mg once daily
Study: 27993829
Drug: Filgotinib 200
Normalized name: nilotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib 200 mg daily
Study: 27993829
Drug: Filgotinib 100
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Filgotinib 100 mg daily
Study: 18443343
Drug: Betamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (4 mg)
Study: 12874677
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 micro g administered as an intravenous bolus)
Study: 10743822
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release codeine (50 mg every 12 h at baseline, escalated to 159 mg every 12 h at final assessment)
Study: 9206057
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (n = 344, Group II)
Study: 2996028
Drug: ACTH 4‐9
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH 4‐9 analog (ORG 2766) 40 mg
Study: 30232113
Drug: High-flow heated
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow heated and humidified nasal oxygen (HFHO) therapy
Study: 27152759
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) infusion at 0.25 μg/kg/hour for 96 hours starting 1 hour after portal venous reperfusion
Study: 22592665
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg per day increased to 300 mg per day
Study: 22592665
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker (CCB) group with amlodipine increased from 7.5 mg to 10 mg per day
Study: 20348368
Drug: EPA-FFA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-FFA (2 g daily for 6 months)
Study: 1827016
Drug: Sustained-release isradipine
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release isradipine (isradipine SR) 5 mg/day
Study: 1827016
Drug: Sustained-release isradipine
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release isradipine (isradipine SR) 10 mg/day
Study: 6953986
Drug: Daunorubicin (DNR)
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin (DNR) 45 mg/sq m
Study: 6953986
Drug: Daunorubicin (DNR)
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin (DNR) 30 mg/sq m
Study: 6953986
Drug: Adriamycin (ADM)
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin (ADM) 30 mg/sq m
Study: 31479005
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity intervention (9-month curriculum, daily after school)
Study: 30887570
Drug: β-D-Mannuronic acid
Normalized name: D-glucuronic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-D-Mannuronic acid (1000 mg/d, 2 capsules orally for 8 weeks)
Study: 30887570
Drug: β-D-Mannuronic acid
Normalized name: D-glucuronic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-D-Mannuronic acid therapy
Study: 21873264
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg plus daily glucocorticosteroids
Study: 21873264
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus daily glucocorticosteroids
Study: 20008203
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonists (warfarin) for patients with antiphospholipid antibodies and venous thromboembolism
Study: 20008203
Drug: Aspirin or
Normalized name: aspirin Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin or warfarin for ischemic stroke
Study: 20008203
Drug: Prophylactic-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic-dose heparin and aspirin for women with recurrent pregnancy loss
Study: 20008203
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy in patients with APS-associated thrombocytopenia
Study: 16355282
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate 1 mg/kg/day
Study: 16355282
Drug: Intravenous pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pamidronate 3 mg/kg/4 months
Study: 15104556
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose therapy (1 mg/day oestradiol‐17 beta with 5 or 10 mg/day dydrogesterone)
Study: 15104556
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose therapy (2 mg/day oestradiol‐17 beta with 10 or 20 mg/day dydrogesterone)
Study: 8273241
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intra-articular morphine
Study: 8273241
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intra-articular morphine
Study: 3304381
Drug: Ketotifen, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen, 1 mg twice daily
Study: 31741136
Drug: Serum albumin
Normalized name: Serum albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum albumin level (per SD increase of 0.27 g/dL)
Study: 31741136
Drug: Mendelian randomization
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mendelian randomization analysis (per 1 g/dL increase of albumin)
Study: 30138665
Drug: Colistin methanesulfonate
Normalized name: Colistin methanesulfonic acid
DrugBank: Colistimethate (DB01111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin methanesulfonate (CMS) 2 MIU + azidothymidine (AZT) 100 mg
Study: 28235206
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg omega-3 fatty acids from flaxseed oil containing 400 mg α-linolenic acid, twice a day for 12 weeks
Study: 28235206
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice a day for 12 weeks
Study: 28235206
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg omega-3 fatty acids from flaxseed oil
Study: 26356057
Drug: Indomethacin per
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin per rectum and opiate analgesic intramuscularly
Study: 23924660
Drug: Ribavirin dosage
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin dosage reduction (n = 249)
Study: 23924660
Drug: Erythropoietin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin therapy (n = 251)
Study: 23924660
Drug: Erythropoietin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin therapy (n = 295)
Study: 23924660
Drug: No erythropoietin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No erythropoietin therapy (n = 392)
Study: 16557151
Drug: Pflex/LTV (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pflex/LTV (low tidal volume 5-8 mL/kg PBW, PEEP set at Pflex + 2 cm H2O)
Study: 16557151
Drug: Control (tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (tidal volume 9-11 mL/kg PBW, PEEP >= 5 cm H2O)
Study: 15121371
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and laser treatment
Study: 11699982
Drug: Antimicrobial agents
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial agents
Study: 11336589
Drug: New antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antimicrobial compounds
Study: 9805220
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of red wine
Study: 9805220
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of malt whisky
Study: 8301543
Drug: 0 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/70 kg morphine
Study: 8301543
Drug: 2.5 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/70 kg morphine
Study: 8301543
Drug: 5.0 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg/70 kg morphine
Study: 8301543
Drug: 10 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/70 kg morphine
Study: 2899239
Drug: Inhaled frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled frusemide (28 mg)
Study: 2899239
Drug: Inhaled frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled frusemide (14 mg)
Study: 2899239
Drug: Oral frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral frusemide (20 mg)
Study: 29276227
Drug: Constant Current
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant Current (CC) system
Study: 18297290
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BTX-A) injections at different doses
Study: 14564313
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 1800 mg/day in addition to HMG-CoA reductase inhibitor
Study: 14564313
Drug: HMG-CoA reductase
Normalized name: HMG-CoA reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG-CoA reductase inhibitor
Study: 11091245
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of blood transfusion and subsequent development of infection
Study: 26028361
Drug: 2.4 g
Normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g amino acids/(kg·d) plus 2 g lipids/(kg·d)
Study: 26028361
Drug: 3.6 g
Normalized name: ALCOHOL 3.6 g EXTRACORPOREAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 g amino acids/(kg·d) plus 2 g lipids/(kg·d)
Study: 22512461
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) plus systemic amoxicillin + metronidazole (SMA)
Study: 22512461
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) plus no adjunctive treatment
Study: 12809960
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg TID with Fluvastatin 80 mg/d
Study: 8674343
Drug: Normothermic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermic treatment group
Study: 30608337
Drug: Maggot therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maggot therapy (MT)
Study: 27253669
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral contraceptive pill (OCP)
Study: 24297663
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 50 mg/day
Study: 20709087
Drug: 800ml of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800ml of paper filtered coffee daily for 5 days
Study: 12062881
Drug: Low-dose haloperidol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose haloperidol (mean dose 5.0 mg at 6 months)
Study: 12062881
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean dose 6.0 mg at 6 months)
Study: 9088582
Drug: Zolmitriptan single
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolmitriptan single dose 10 mg
Study: 29788346
Drug: Ebola vaccine
Normalized name: ebola vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebola vaccine
Study: 24518169
Drug: Early insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early insulin treatment
Study: 18180864
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine added to current oral antidiabetic drugs (OAD) regimen
Study: 18180864
Drug: Increased dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dosage of oral antidiabetic drugs (OAD)
Study: 15858073
Drug: Phonics treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonics treatment package
Study: 12650495
Drug: Suprascapular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprascapular nerve block with 5 mL 0.5% bupivacaine with epinephrine
Study: 12650495
Drug: Piroxicam patch
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam patch (48 mg) applied to each shoulder
Study: 10792383
Drug: HAART plus
Normalized name: Tri-Heart Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART plus low dose rIL-2 (1000 000 U/daily) (n = 8)
Study: 8680492
Drug: Jet injector
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet injector for morphine (8 mg, 5 mg if weight ≤ 65 kg)
Study: 8680492
Drug: Needle and
Normalized name: syringe with needle and cannula, disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle and syringe for morphine (8 mg, 5 mg if weight ≤ 65 kg)
Study: 8680492
Drug: Jet injector
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet injector for heparin (3500 U every 8 hours for 5 days)
Study: 8680492
Drug: Needle and
Normalized name: syringe with needle and cannula, disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle and syringe for heparin (3500 U every 8 hours for 5 days)
Study: 1847278
Drug: Succinylcholine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (1 mg/kg) plus Pancuronium (100 micrograms/kg)
Study: 1847278
Drug: Succinylcholine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (1 mg/kg) plus Pipecuronium (80 micrograms/kg)
Study: 23270288
Drug: Fränkel II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fränkel II appliance treatment for 1 year 11 months
Study: 20231536
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of ramipril and telmisartan
Study: 12645641
Drug: New devices
Approvals — FDA: no, EMA: no, PMDA: no
Description: New devices (thrombectomy devices, drug-eluting stents)
Study: 10484395
Drug: Active rectal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rectal distension
Study: 10484395
Drug: Sham rectal
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham rectal distension
Study: 9139277
Drug: Responsive patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responsive patients (on one or two drugs)
Study: 9139277
Drug: Resistant patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant patients (on three or more drugs)
Study: 9139277
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with essential hypertension resistant to treatment
Study: 9139277
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with essential hypertension responsive to antihypertensive treatment
Study: 6315911
Drug: Marijuana (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana (20 mg doses of delta‐9 tetrahydrocannabinol)
Study: 31542292
Drug: Early combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early combination therapy with vildagliptin (50 mg twice daily) and metformin (stable daily dose of 1000 mg, 1500 mg, or 2000 mg)
Study: 31542292
Drug: Initial metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial metformin monotherapy (stable daily dose of 1000 mg, 1500 mg, or 2000 mg) and placebo twice daily
Study: 31542292
Drug: Early combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early combination therapy with vildagliptin and metformin
Study: 31542292
Drug: Initial metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial metformin monotherapy
Study: 16522696
Drug: Oral conivaptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral conivaptan 40 mg/d
Study: 16522696
Drug: Oral conivaptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral conivaptan 80 mg/d
Study: 30103252
Drug: Oral apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral apixaban
Study: 31456010
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mizolastine (10 mg/day), proteoglycan (1.2 g, 3 times/day), calcium gluconate (10 mg/day), vitamin D3 (10 mg/week)
Study: 31456010
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mizolastine and proteoglycan
Study: 23928867
Drug: Metformin added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin added to intensive insulin therapy
Study: 19538812
Drug: 300 g
Normalized name: Zantac 300 GELdose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 g additional fruit and vegetables per day
Study: 18856162
Drug: Efalizumab therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab therapy
Study: 2659104
Drug: Salvage hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage hormonal therapy
Study: 2659104
Drug: Retreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retreatment with CFP as salvage chemotherapy
Study: 28154373
Drug: Tiotropium +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium + Olodaterol 2.5/5 or 5/5 μg
Study: 28154373
Drug: Tiotropium 2.5
Normalized name: TIOTROPIUM 2.5MCG/ACTUAT 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 2.5 or 5 μg
Study: 28154373
Drug: Tiotropium +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium + Olodaterol 5/5 μg
Study: 18437797
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of implants
Study: 20467635
Drug: Early loading
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loading of implants
Study: 14652118
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at a subhypnotic dose (1.0 mg/kg/hr)
Study: 11742887
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg) plus pyridoxine (250 mg)
Study: 8498758
Drug: Minocycline, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline, 100 mg nightly for 7 days
Study: 8498758
Drug: Doxycycline, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline, 100 mg twice daily for 7 days
Study: 3281765
Drug: Saline bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline bolus followed by saline infusion
Study: 3281765
Drug: 0.4 microgram.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 microgram.kg‐1 naloxone bolus followed by 0.4 microgram.kg‐1.hr‐1 naloxone infusion
Study: 3281765
Drug: 2.0 micrograms.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 micrograms.kg‐1 naloxone bolus followed by 2.0 micrograms.kg‐1.hr‐1 naloxone infusion
Study: 3281765
Drug: 4.0 micrograms.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 micrograms.kg‐1 naloxone bolus followed by 4.0 micrograms.kg‐1.hr‐1 naloxone infusion
Study: 29145038
Drug: Molecular targeted
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular targeted agents (MTAs)
Study: 30271119
Drug: Other molecular
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Other molecular targeted agents (MTAs)
Study: 29132441
Drug: Early screening
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early screening and treatment for genital Chlamydia trachomatis infection over 24 months.
Study: 25160589
Drug: MK‐3577 (0‐900
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐3577 (0‐900 mg)
Study: 25160589
Drug: Glucagon, octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon, octreotide (Sandostatin), and basal insulin infusion